Cargando…

Inflammasome Signaling: A Novel Paradigm of Hub Platform in Innate Immunity for Cancer Immunology and Immunotherapy

Inflammasomes are fundamental innate immune mechanisms that promote inflammation and induce an inflammatory form of programmed cell death, pyroptosis. Pyroptotic inflammasome has been reported to be closely associated with tumorigenesis and prognosis of multiple cancers. Emerging studies show that t...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ying, Lv, Jiao, Shi, Weikai, Feng, Jia, Liu, Mingxi, Gan, Shenao, Wu, Hongjin, Fan, Weiwei, Shi, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8374049/
https://www.ncbi.nlm.nih.gov/pubmed/34421915
http://dx.doi.org/10.3389/fimmu.2021.710110
_version_ 1783740032113180672
author Li, Ying
Lv, Jiao
Shi, Weikai
Feng, Jia
Liu, Mingxi
Gan, Shenao
Wu, Hongjin
Fan, Weiwei
Shi, Ming
author_facet Li, Ying
Lv, Jiao
Shi, Weikai
Feng, Jia
Liu, Mingxi
Gan, Shenao
Wu, Hongjin
Fan, Weiwei
Shi, Ming
author_sort Li, Ying
collection PubMed
description Inflammasomes are fundamental innate immune mechanisms that promote inflammation and induce an inflammatory form of programmed cell death, pyroptosis. Pyroptotic inflammasome has been reported to be closely associated with tumorigenesis and prognosis of multiple cancers. Emerging studies show that the inflammasome assembly into a higher-order supramolecular complex has been utilized to evaluate the status of the innate immune response. The inflammasomes are now regarded as cellular signaling hubs of the innate immunity that drive the production of inflammatory cytokines and consequent recruitment of immune cells to the tumor sites. Herein, we provided an overview of molecular characteristics and biological properties of canonical and non-canonical inflammasome signaling in cancer immunology and immunotherapy. We also focus on the mechanism of regulating pyroptotic inflammasome in tumor cells, as well as the potential roles of inflammasome-mediated pyroptotic cell death in cancers, to explore the potential diagnostic and therapeutic markers contributing to the prevention and treatment of cancers.
format Online
Article
Text
id pubmed-8374049
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-83740492021-08-20 Inflammasome Signaling: A Novel Paradigm of Hub Platform in Innate Immunity for Cancer Immunology and Immunotherapy Li, Ying Lv, Jiao Shi, Weikai Feng, Jia Liu, Mingxi Gan, Shenao Wu, Hongjin Fan, Weiwei Shi, Ming Front Immunol Immunology Inflammasomes are fundamental innate immune mechanisms that promote inflammation and induce an inflammatory form of programmed cell death, pyroptosis. Pyroptotic inflammasome has been reported to be closely associated with tumorigenesis and prognosis of multiple cancers. Emerging studies show that the inflammasome assembly into a higher-order supramolecular complex has been utilized to evaluate the status of the innate immune response. The inflammasomes are now regarded as cellular signaling hubs of the innate immunity that drive the production of inflammatory cytokines and consequent recruitment of immune cells to the tumor sites. Herein, we provided an overview of molecular characteristics and biological properties of canonical and non-canonical inflammasome signaling in cancer immunology and immunotherapy. We also focus on the mechanism of regulating pyroptotic inflammasome in tumor cells, as well as the potential roles of inflammasome-mediated pyroptotic cell death in cancers, to explore the potential diagnostic and therapeutic markers contributing to the prevention and treatment of cancers. Frontiers Media S.A. 2021-08-05 /pmc/articles/PMC8374049/ /pubmed/34421915 http://dx.doi.org/10.3389/fimmu.2021.710110 Text en Copyright © 2021 Li, Lv, Shi, Feng, Liu, Gan, Wu, Fan and Shi https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Li, Ying
Lv, Jiao
Shi, Weikai
Feng, Jia
Liu, Mingxi
Gan, Shenao
Wu, Hongjin
Fan, Weiwei
Shi, Ming
Inflammasome Signaling: A Novel Paradigm of Hub Platform in Innate Immunity for Cancer Immunology and Immunotherapy
title Inflammasome Signaling: A Novel Paradigm of Hub Platform in Innate Immunity for Cancer Immunology and Immunotherapy
title_full Inflammasome Signaling: A Novel Paradigm of Hub Platform in Innate Immunity for Cancer Immunology and Immunotherapy
title_fullStr Inflammasome Signaling: A Novel Paradigm of Hub Platform in Innate Immunity for Cancer Immunology and Immunotherapy
title_full_unstemmed Inflammasome Signaling: A Novel Paradigm of Hub Platform in Innate Immunity for Cancer Immunology and Immunotherapy
title_short Inflammasome Signaling: A Novel Paradigm of Hub Platform in Innate Immunity for Cancer Immunology and Immunotherapy
title_sort inflammasome signaling: a novel paradigm of hub platform in innate immunity for cancer immunology and immunotherapy
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8374049/
https://www.ncbi.nlm.nih.gov/pubmed/34421915
http://dx.doi.org/10.3389/fimmu.2021.710110
work_keys_str_mv AT liying inflammasomesignalinganovelparadigmofhubplatformininnateimmunityforcancerimmunologyandimmunotherapy
AT lvjiao inflammasomesignalinganovelparadigmofhubplatformininnateimmunityforcancerimmunologyandimmunotherapy
AT shiweikai inflammasomesignalinganovelparadigmofhubplatformininnateimmunityforcancerimmunologyandimmunotherapy
AT fengjia inflammasomesignalinganovelparadigmofhubplatformininnateimmunityforcancerimmunologyandimmunotherapy
AT liumingxi inflammasomesignalinganovelparadigmofhubplatformininnateimmunityforcancerimmunologyandimmunotherapy
AT ganshenao inflammasomesignalinganovelparadigmofhubplatformininnateimmunityforcancerimmunologyandimmunotherapy
AT wuhongjin inflammasomesignalinganovelparadigmofhubplatformininnateimmunityforcancerimmunologyandimmunotherapy
AT fanweiwei inflammasomesignalinganovelparadigmofhubplatformininnateimmunityforcancerimmunologyandimmunotherapy
AT shiming inflammasomesignalinganovelparadigmofhubplatformininnateimmunityforcancerimmunologyandimmunotherapy